Pantoprazol Elac (Pantoprazole)

Pantoprazol Elac is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related gastrointestinal conditions:

• Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of the oesophageal lining.
• Erosive oesophagitis: accelerates healing of erosive lesions in the oesophagus.
• Peptic ulcer disease (duodenal and gastric ulcers): supports ulcer healing and reduces recurrence.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with this rare endocrine disorder.

• Pantoprazole selectively inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells in the stomach. By binding covalently to the pump’s cysteine residues, it blocks the final step of acid production, leading to a sustained increase in gastric pH and reduced acidity in the gastrointestinal tract.

Pantoprazol Elac may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhoea: loose stools occurring during early treatment.
• Nausea: occasional feeling of queasiness.
• Abdominal pain: mild discomfort in the stomach area.
• Flatulence: increased intestinal gas.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing.
• Clostridioides difficile infection: persistent watery diarrhoea.
• Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat.
• Bone fractures: increased risk with long‑term use.
• Liver enzyme elevation: signs of hepatic stress.
• Acute interstitial nephritis: kidney inflammation presenting with fever and rash.

When prescribing Pantoprazol Elac, clinicians should consider several safety aspects:

• Renal impairment: adjust monitoring if patient has reduced kidney function.
• Hepatic impairment: use with caution in patients with liver disease.
• Long‑term therapy: evaluate need for periodic assessment of bone density and magnesium levels.
• Drug interactions: review concomitant medications for potential CYP‑related effects.
• Pregnancy and lactation: limit use to situations where benefit outweighs potential risk.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Pantoprazol Elac can affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid)

• Antifungal agents (ketoconazole, itraconazole): reduced absorption due to higher gastric pH.
• HIV protease inhibitors (atazanavir, nelfinavir): decreased efficacy.
• Clopidogrel: diminished antiplatelet activity.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR values.
• Methotrexate: reduced renal clearance may raise serum levels.
• Digoxin: slight increase in serum concentration.
• Oral contraceptives: potential decrease in hormonal efficacy.